FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a pharmaceutical composition for treating malignant growths containing 1.22–35.7 wt% sodium dichloroacetate, 0.028–0.1 wt% Doxorubicin-Teva preparation in the form of a lyophilizate for preparing an injection solution and rest 0.9 %-solution of sodium chloride.
EFFECT: invention provides higher anti-tumor activity ensured by the potentiating sodium dichloroacetate with cytotoxic activity of doxorubicin with the possibility of using doxorubicin in lower doses.
1 cl, 3 ex, 1 tbl, 3 dwg
Title | Year | Author | Number |
---|---|---|---|
PHARAMCEUTICAL COMPOSITION FOR TREATMENT OF ONCOLOGICAL DISEASES | 2012 |
|
RU2484814C1 |
PHARMACEUTICAL COMPOSITION FOR ONCOLOGICAL DISEASES | 2011 |
|
RU2463053C1 |
METHOD FOR PROCESSING TUMOUR CELLS | 2016 |
|
RU2632429C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT GROWTHS OF PROSTATE GLANDS | 2015 |
|
RU2589266C1 |
AGENT FOR TARGETED THERAPY OF MALIGNANT GROWTHS | 2018 |
|
RU2699558C2 |
METHOD OF TREATING MELANOMA IN VIVO | 2023 |
|
RU2824428C2 |
METHOD OF TREATING A DISEASE USING A COMPOUND HAVING AN EFFECT ON GLYCOLYSIS | 2016 |
|
RU2723215C2 |
COMPOSITION BASED ON AMINO-NITROXYL COMPLEX OF PLATINUM AND DOXORUBICIN AND METHOD OF TREATING TUMORS | 2016 |
|
RU2726826C2 |
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
Authors
Dates
2019-12-25—Published
2019-04-24—Filed